Background The high prevalence of anaemia and the increased morbidity and mortality associated with anaemia during AIDS has been well described yet there has been little information about anaemia and changes in haemoglobin levels during acute and early HIV-1 infection. Methods HIV-negative women (n = 245) were enrolled into an observational cohort as part of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Acute Infection Study. Acute infection was diagnosed following a positive HIV RNA PCR in the absence of antibodies, or detection of HIV-1 antibodies within 3 months of a previously negative antibody test. Haemotologic parameters were assessed before infection and at regular intervals in the first twelve months of HIV infection. Results Fifty-seven participants with acute HIV infection were identified at a median of 14.5 days post-infection (range 10–81) and were enrolled in the CAPRISA Acute Infection cohort at a median of 41 days post-infection (range 15–104). Mean haemoglobin prior to HIV-1 infection was 12.7 g/dL, with a mean decline of 0.46 g/dL following infection. The prevalence of anaemia increased from 25.0% prior to HIV-1 infection to 52.6% at 3 months post-infection, 61.1% at 6 months post-infection, and 51.4% at 12 months post-infection. Conclusions Haematologic derangements and anaemia with a trend towards iron deficiency are common with acute HIV-1 subtype C infection in this small cohort. The negative impact of anaemia concurrent with established HIV infection upon morbidity and mortality has been well documented but the prognostic potential and long-term effects of anaemia during acute HIV-1 infection remain unknown.
References
[1]
Kreuzer KA, Rockstroh JK (1997) Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 75: 179–87.
[2]
Savarino A, Pescarmona GP, Boelaert JR (1999) Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 17: 279–287.
[3]
Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, et al. (2005) Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 39(5): 620–625.
[4]
Moore R (1999) Human immunodeficiency virus infection, anemia, and survival. Clin Inf Dis 29: 44–49.
[5]
Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, et al. (2002) Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Inf Dis 34: 260–66.
[6]
Lundgren JD, Mocroft A (2003) Anemia and survival in human immunodeficiency virus. Clin Inf Dis 37: Suppl 4S297–303.
[7]
Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, et al. (1999) Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 13: 943–950.
[8]
Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW (1998) Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 91(1): 301–308.
[9]
Zhou J, Kumarasamy N, TREAT Asia HIV Observational Database (2005) Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine 6: 216–223.
[10]
O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, et al. (2005) Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 40(2): 219–225.
[11]
WHO (1992) The Prevalence of Anaemia in Women: A Tabulation of Available Information. in Document WHO/MCH/MSM/92.2. Geneva: World Health Organization.
[12]
Bahner I, Kearns K, Coutinho S, Leonard EH, Kohn DB (1997) Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1 induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 90(5): 1787–98.
[13]
Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, et al. (1997) Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. British J Hematol 96: 235–239.
[14]
Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, et al. (1996) Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 87(3): 919–925.
[15]
Moses A, Nelson J, Bagby GC Jr (1998) The influence of human immunodeficiency virus-1 on hematopoeisis. Blood 91(5): 1479–95.
[16]
Deschamps M, Fitzgerald DW, Pape JW, Johnson WD Jr (2000) HIV infection in Haiti: natural history and disease progression. AIDS 14(16): 2515–2521.
[17]
Lawn SD, Butera ST, Folks TM (2001) Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Reviews 14(4): 753–777.
[18]
Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, et al. (2004) Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 37(2): 1245–52.
[19]
Semba RD, Martin BK, Kempen JH, Thorne JE, Wu AW (2005) The impact of anemia on energy and physical functioning in individuals with AIDS. Arch Intern Med 165: 2229–2236.
